Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Autologous pancreatic islets cells
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved
Sponsor : Orgenesis
Deal Size : $16.3 million
Deal Type : Acquisition
Details : Following closing of the Transaction, Orgenesis plans to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well.
Brand Name : Kyslecel
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 29, 2020
Lead Product(s) : Autologous pancreatic islets cells
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved
Sponsor : Orgenesis
Deal Size : $16.3 million
Deal Type : Acquisition
Lead Product(s) : KT-PC-301
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Koligo Therapeutics to Develop Personalized Cell Therapy for the Treatment of COVID-19
Details : KT-PC-301 is a cell therapy that is derived from a patient’s own adipose (fat) tissue. The planned phase 2 trial will enroll 75 patients and evaluate the safety and efficacy of KT-PC-301 as compared to placebo.
Brand Name : KT-PC-301
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 21, 2020
Lead Product(s) : KT-PC-301
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
